Quipt Home Medical Corp. (NASDAQ:QIPT) Q1 2024 Results Conference Call February 15, 2024 10:00 AM ET
Company Participants
Greg Crawford - Chairman, CEO
Hardik Mehta - CFO
Conference Call Participants
Richard Close - Canaccord Genuity
Cooper Douglas - Beacon Securities
Michael Freeman - Raymond James
Julian Hung - Stifel
Stefan Quenneville - Echelon Capital Markets
Operator
Thank you for standing by. This is the conference operator. Welcome to the Fiscal Q1 2024 Earnings Results Conference Call for Quipt Home Medical Corp. As a reminder, all participants are in a listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity for analysts to ask questions. [Operator Instructions]
We remind you that the remarks today will include forward-looking statements that are subject to important risks and uncertainties. For more information on these risks and uncertainties, please see the reader advisory at the bottom of the Company's results news release. The Company's actual performance could differ materially from these statements.
At this point, I would like to turn the call over to Chairman and Chief Executive Officer, Greg Crawford. Please go ahead.
Greg Crawford
Thank you, operator, and thank you all for joining us today on the call. My name is Greg Crawford, and I'm the Chairman and Chief Executive Officer of Quipt Home Medical.
Joining me today is Hardik Mehta, our Chief Financial Officer. Quipt Home Medical is a diversified health care services company, providing a full spectrum of home medical equipment and services to patients in the comfort of their own homes across the United States.
At Quipt, our model is centered around delivering clinical excellence and we drive this through our patient-centric ecosystem, leveraging technology-enabled equipment solutions in conjunction with our specialized clinical respiratory programs to effectively treat patients at home in a way that best suits their needs.
At present, approximately 80% of our product mix is dedicated to respiratory care, reflecting our dedication to meeting the needs of those with cardio and pulmonary conditions. Our remarkable team exceeding over 1,200 is the driving force behind our success, bringing our vision to life daily with an unyielding commitment to superior patient care. We continue to achieve consistent financial and operational results driven by our resilient business model.
As of fiscal Q1, our recurring revenue base sits at 83% of total revenue representing the strength and predictability of our financial foundation. Moreover, driving our market share growth is the targeted go-to-market strategies we deploy and end-to-end respiratory solutions we offer in the marketplace.